Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ID1-H51H8 | Human | Human IDH1 (R132C) Protein, His Tag (MALS verified) |
|
||
ID1-H51H6 | Human | Human IDH1 Protein, His Tag (active enzyme, MALS verified) |
|
The purity of Human IDH1 (R132C), His Tag (Cat. No. ID1-H51H8) is more than 85% and the molecular weight of this protein is around 85-100 kDa verified by SEC-MALS.
The purity of Human IDH1, His Tag (Cat. No. ID1-H51H6) is more than 85% and the molecular weight of this protein is around 90-100 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ivosidenib | AG-120; CS-3010; S-95031; CS 3010 | Approved | Agios Pharmaceuticals Inc | Tibsovo, 拓舒沃, Tidhesco, Tuoshuvo, TIBSOVO, Tosuvo | United States | Leukemia, Myeloid, Acute | Servier Pharmaceuticals Llc | 2018-07-20 | Histiocytosis, Langerhans-Cell; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Lymphoma, Non-Hodgkin; Neoplasms, Neuroepithelial; Glioma; Leukemia, Myeloid, Acute; Bile Duct Neoplasms; Hepatic Insufficiency; Osteosarcoma; Sarcoma, Ewing; Cholangiocarcinoma; Pancytopenia; Sarcoma; Neuroblastoma; Ependymoma; Wilms Tumor; Sarcoma, Myeloid; Myelodysplastic Syndromes; Myeloproliferative Disorders; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Rhabdomyosarcoma; Medulloblastoma; Chondrosarcoma; Hematologic Neoplasms; Leukemia; Leukemia, Myeloid | Details |
Olutasidenib | FT-2102 | Approved | Forma Therapeutics Holdings Inc | Rezlidhia | United States | Leukemia, Myeloid, Acute | Rigel Pharmaceuticals Inc | 2022-12-01 | Chondrosarcoma; Leukemia, Promyelocytic, Acute; Irritable Bowel Syndrome; Myelodysplastic Syndromes; Diarrhea; Leukemia, Myeloid, Acute | Details |
Ivosidenib | AG-120; CS-3010; S-95031; CS 3010 | Approved | Agios Pharmaceuticals Inc | Tibsovo, 拓舒沃, Tidhesco, Tuoshuvo, TIBSOVO, Tosuvo | United States | Leukemia, Myeloid, Acute | Servier Pharmaceuticals Llc | 2018-07-20 | Histiocytosis, Langerhans-Cell; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Lymphoma, Non-Hodgkin; Neoplasms, Neuroepithelial; Glioma; Leukemia, Myeloid, Acute; Bile Duct Neoplasms; Hepatic Insufficiency; Osteosarcoma; Sarcoma, Ewing; Cholangiocarcinoma; Pancytopenia; Sarcoma; Neuroblastoma; Ependymoma; Wilms Tumor; Sarcoma, Myeloid; Myelodysplastic Syndromes; Myeloproliferative Disorders; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Rhabdomyosarcoma; Medulloblastoma; Chondrosarcoma; Hematologic Neoplasms; Leukemia; Leukemia, Myeloid | Details |
Olutasidenib | FT-2102 | Approved | Forma Therapeutics Holdings Inc | Rezlidhia | United States | Leukemia, Myeloid, Acute | Rigel Pharmaceuticals Inc | 2022-12-01 | Chondrosarcoma; Leukemia, Promyelocytic, Acute; Irritable Bowel Syndrome; Myelodysplastic Syndromes; Diarrhea; Leukemia, Myeloid, Acute | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
HMPL-306 | HMPL-306 | Phase 3 Clinical | Hutchison Medipharma Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
TQB-3454 | TQB-3454; CT-2755 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Hematologic Neoplasms; Solid tumours; Biliary Tract Neoplasms; Myelodysplastic Syndromes; Bile Duct Neoplasms; Leukemia, Myeloid, Acute | Details |
Vorasidenib (Servier) | AGI-23088; S-95032; S95032; AG-881 | Phase 3 Clinical | Agios Pharmaceuticals Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Astrocytoma; Hepatic Insufficiency; Glioma; Leukemia, Myeloid, Acute | Details |
Safusidenib | DS-1001b; DS-1001; AB-218 | Phase 2 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Biliary Tract Neoplasms; Glioma | Details |
BAY-1436032 | BAY-1436032 | Phase 1 Clinical | Bayer AG | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
TQB-3455 | TQB-3455; CT-2426 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
IDH-305 | IDH-305 | Phase 1 Clinical | Novartis Pharma Ag | Neoplasms; Leukemia, Myeloid, Acute; Glioma | Details |
BPI-221351 | BPI-221351 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Glioma | Details |
KY-100001 | KY-100001 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Solid tumours | Details |
HH-2301 | HH-2301; HH2301 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Biliary Tract Neoplasms; Solid tumours; Chondrosarcoma; Glioma | Details |
LY-3410738 | LY-3410738 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Chondrosarcoma; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Cholangiocarcinoma; Leukemia, Myeloid, Acute; Glioma | Details |
HMPL-306 | HMPL-306 | Phase 3 Clinical | Hutchison Medipharma Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
TQB-3454 | TQB-3454; CT-2755 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Hematologic Neoplasms; Solid tumours; Biliary Tract Neoplasms; Myelodysplastic Syndromes; Bile Duct Neoplasms; Leukemia, Myeloid, Acute | Details |
Vorasidenib (Servier) | AGI-23088; S-95032; S95032; AG-881 | Phase 3 Clinical | Agios Pharmaceuticals Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Astrocytoma; Hepatic Insufficiency; Glioma; Leukemia, Myeloid, Acute | Details |
Safusidenib | DS-1001b; DS-1001; AB-218 | Phase 2 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Biliary Tract Neoplasms; Glioma | Details |
BAY-1436032 | BAY-1436032 | Phase 1 Clinical | Bayer AG | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
TQB-3455 | TQB-3455; CT-2426 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
IDH-305 | IDH-305 | Phase 1 Clinical | Novartis Pharma Ag | Neoplasms; Leukemia, Myeloid, Acute; Glioma | Details |
BPI-221351 | BPI-221351 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Glioma | Details |
KY-100001 | KY-100001 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Solid tumours | Details |
HH-2301 | HH-2301; HH2301 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Biliary Tract Neoplasms; Solid tumours; Chondrosarcoma; Glioma | Details |
LY-3410738 | LY-3410738 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Chondrosarcoma; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Cholangiocarcinoma; Leukemia, Myeloid, Acute; Glioma | Details |
This web search service is supported by Google Inc.